Lack of interaction between orlistat and oral contraceptives

European Journal of Clinical Pharmacology

Volumn 50, Issue 5, 1996, Pages 421-424

  Hartmann, D ^a   Guzelhan C ^a   Zuiderwijk, P B M ^b   Odink, J ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b TNO   (Netherlands)

Author keywords

Interaction; Lipase inhibitor; Oral contraceptives; Orlistat

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS LYNESTRENOL; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE; TETRAHYDROLIPSTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG INTERACTION; FEMALE; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OVULATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BIOLOGY; CONTRACEPTION; CONTRACEPTIVE METHODS--PHARMACODYNAMICS; CONTRACEPTIVE MODE OF ACTION; DEVELOPED COUNTRIES; DOUBLE-BLIND STUDIES; DRUG INTERACTIONS; DRUGS; ENZYME INHIBITORS--PHARMACODYNAMICS; ENZYMES AND ENZYME INHIBITORS; EUROPE; FAMILY PLANNING; NETHERLANDS; ORAL CONTRACEPTIVES, COMBINED--PHARMACODYNAMICS; ORAL CONTRACEPTIVES--PHARMACODYNAMICS; OVULATION SUPPRESSION; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; STUDIES; TREATMENT; WESTERN EUROPE;

ADULT; ANALYSIS OF VARIANCE; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LACTONES; LUTEINIZING HORMONE; PROGESTERONE; RADIOIMMUNOASSAY;

EID: 0029973880     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050134     Document Type: Article

References (19)

1. American Heart Association (1986) Dietary guidelines for healthy American adults: A statement for physicians and health professionals by the Nutrition Committee. American Heart Association. Circulation 74:1465A 1468A
2. Borgström B (1988) Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 962:308-316
3. Drent ML, van der Veen BA (1993) Lipase inhibition: a novel concept in the treatment of obesity. Int J Obesity 17:241 244
4. Güzelhan C, Crijns HJMJ, Peeters PAM, Jonkman JHG, Hartmann D (1991) Pharmacological activity (inhibition of fat absorption) and tolerability in healthy volunteers of tetrahydrolipstatin (THL) A specific lipase inhibitor. Int J Obesity 15 [Suppl 1]:29
5. Güelhan C, Odink J, Niestijl Jansen-Zuidema JJ, Hartmann D (1994) Influence of dietary composition on the inhibition of fat absorption by orlistat. J Int Med Res 22:255 265
6. Hadvary P, Lengsfeld H, Wolfer H (1988) Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 256:357-361
7. Hartmann D, Güzelhan C, Crijns HJMJ, Peeters PAM, Jonkman JHG (1993a) Comparison of galenic formulations of orlistat (tetrahydrolipstatin) A pharmacological approach. Drug Invest 5:44 50
8. Hartmann D, Hussain Y, Güzelhan C, Odink J (1993b) Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 36:266 270
9. Hauptman J, Jeunet F, Hartmann D (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor, Ro 18 0647 (tetrahydrolipstain). Am J Clin Nutr 5:309S 313S
10. Hogan S, Fleury A, Hadvary P (1987) Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obesity 11 [Suppl 3]:35 42
11. Hussain Y, Güzelhan C, Odink J, van der Beek EJ, Hartmann D (1994) Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat. J Clin Pharmacol 34:1121 1125
12. Jandacek RJ (1982) The effect of nonabsorbable lipids on the intestinal absorption of lipophiles. Drug Metab Rev 13:695 714
13. Meier MK, Blum-Kälin D, Bremer K, Isler D, Joly R, Keller-Rupp P, Lengsfeld H (1991) Preclinical profile of the lipase inhibitor tetrahydrolipstatin (Ro 18 0647, THL), a potential drug for the treatment of obesity. Int J Obesity 15 [Suppl 1]:31
14. 14C-labelled orlistat in healthy volunteers. Pharm Res 10 [Suppl]:S335
15. Miller KW, Williams DS, Carter SB, Jones MB, Mishell DR (1990) The effect of olestra on systemic levels of oral contraceptives. Clin Pharmacol Ther 48:34 40
16. Roberts JR, Leff RD (1989) Influence of absorbable and nonabsorbable lipids and lipid-like substances on drug availability. Clin Pharmacol Ther 45:299-304
17. Ross GT, Vande Wiele RL (1974) The ovaries. In: Williams RH (ed) Textbook of endocrinology, 5th ed Saunders, Philadelphia, pp 368 422
18. Study Group European Atherosclerosis Society (1987) Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. Eur Heart J 8:77 88
19. The New England Journal of Medicine SI Unit Conversion Guide. Massachusetts, Medical Society, Waltham, Massachusetts, USA, 1992, pp. 56 107